Acceleron Pharma

Acceleron to Host Virtual Research and Development (R&D) Day on June 22, 2021

Retrieved on: 
Tuesday, June 8, 2021
Health, General Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Health sciences, Health, Clinical pharmacology, Clinical research, Clinical trial, Design of experiments, Pharmaceutical industry, Acceleron Pharma

To register for the event, please visit the R&D Day 2021 Registration Site .

Key Points: 
  • To register for the event, please visit the R&D Day 2021 Registration Site .
  • Gomberg, Humbert, and McLaughlin are investigators in multiple ongoing and planned Acceleron-sponsored clinical trials and are paid consultants to Acceleron.
  • Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases.
  • Acceleron focuses its research, development, and commercialization efforts in pulmonary and hematologic diseases.

Acceleron Announces First Quarter 2021 REBLOZYL® Net Sales

Retrieved on: 
Thursday, April 29, 2021
Biotechnology, Pharmaceutical, Health, Companies, Bristol Myers Squibb, Life sciences, Acceleron Pharma, Luspatercept, Squib, Health care

b'Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL\xc2\xae(luspatercept-aamt) as reported by its global collaborator, Bristol Myers Squibb, were approximately $112 million for the first quarter ended March 31, 2021.\nAcceleron expects to report royalty revenue of approximately $22.4 million from net sales of REBLOZYL in the first quarter ended March 31, 2021.

Key Points: 
  • b'Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL\xc2\xae(luspatercept-aamt) as reported by its global collaborator, Bristol Myers Squibb, were approximately $112 million for the first quarter ended March 31, 2021.\nAcceleron expects to report royalty revenue of approximately $22.4 million from net sales of REBLOZYL in the first quarter ended March 31, 2021.
  • In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension (PAH), having reported positive topline results of the PULSAR Phase 2 trial.
  • REBLOZYL is part of a global collaboration partnership with Bristol Myers Squibb.
  • Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn .\nThis press release contains forward-looking statements about the Company\'s financial results.

Acceleron to Webcast First Quarter 2021 Financial Results on May 6, 2021

Retrieved on: 
Monday, April 26, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Orphan drugs, Hypertension, Acceleron Pharma, Pulmonary hypertension, PAH, Luspatercept, Pulmonary artery, Health care, Health, Branches of biology

b'Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, May 6, 2021 at 5:00 p.m. EDT to discuss its first quarter 2021 financial results.\nThe webcast will be accessible under "Events & Presentations" in the Investors & Media page of the Company\xe2\x80\x99s website at www.acceleronpharma.com .

Key Points: 
  • b'Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, May 6, 2021 at 5:00 p.m. EDT to discuss its first quarter 2021 financial results.\nThe webcast will be accessible under "Events & Presentations" in the Investors & Media page of the Company\xe2\x80\x99s website at www.acceleronpharma.com .
  • In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension (PAH), having reported positive topline results of the PULSAR Phase 2 trial.
  • REBLOZYL is part of a global collaboration partnership with Bristol Myers Squibb.
  • Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210426005098/en/\n'

Acceleron to Participate in Two Upcoming Healthcare Investor Conferences

Retrieved on: 
Tuesday, February 23, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Acceleron Pharma, Pulmonary hypertension, Companies, Economy of the United States, Health care

Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming virtual healthcare investor conferences.

Key Points: 
  • Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming virtual healthcare investor conferences.
  • A replay of each webcast will be available on the Companys website after the event.
  • Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases.
  • In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension (PAH), having reported positive topline results of the PULSAR Phase 2 trial.

Acceleron to Webcast Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

Retrieved on: 
Wednesday, February 17, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious diseases, Acceleron Pharma, Companies

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, February 25, 2021 at 5:00 p.m. EST to discuss its fourth quarter and full year 2020 financial results.

Key Points: 
  • Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, February 25, 2021 at 5:00 p.m. EST to discuss its fourth quarter and full year 2020 financial results.
  • The webcast will be accessible under "Events & Presentations" in the Investors & Media page of the Companys website at acceleronpharma.com .
  • An archived version of the webcast will be available for replay on the Companys website for approximately one year.
  • Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases.

AVROBIO Announces the Appointment of Diana M. Escolar, M.D. as Chief Medical Officer

Retrieved on: 
Tuesday, January 19, 2021
Research, FDA, Genetics, Clinical trials, Biotechnology, Other Health, Health, Other Science, Science, Dystrophy, Medical terminology, Acceleron Pharma, Muscular dystrophy, Medicine, Health

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Diana M. Escolar, M.D., FAAN, as chief medical officer.

Key Points: 
  • AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Diana M. Escolar, M.D., FAAN, as chief medical officer.
  • Were also looking ahead to our next wave of indications, which target disorders that can cause rapid and devastating neurological damage.
  • She also served as the chief medical officer of Akashi Therapeutics, Inc., the principal medical consultant for Acceleron Pharmas muscular dystrophy program and a senior medical consultant and advisory board member for the muscular dystrophy programs at Shire, Plc.
  • AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Acceleron to Participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021

Retrieved on: 
Monday, January 4, 2021
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Acceleron Pharma

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that Habib Dable, Accelerons President and Chief Executive Officer, will present a corporate overview during the 39th Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that Habib Dable, Accelerons President and Chief Executive Officer, will present a corporate overview during the 39th Annual J.P. Morgan Healthcare Conference.
  • A live webcast of the presentation will be accessible under Events and Presentations in the Investors & Media page of the Company's website at www.acceleronpharma.com .
  • A replay of the webcast will be available following the event on the Acceleron website.
  • Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases.

Acceleron Announces REBLOZYL® (luspatercept-aamt) Virtual Presentations at the 62nd American Society of Hematology Annual Meeting

Retrieved on: 
Wednesday, November 4, 2020
Biotechnology, Pharmaceutical, Health, Stem cells, Branches of biology, Medical specialties, Anemias, Blood, Luspatercept, Transfusion-dependent anemia, Beta thalassemia, Red blood cell, Thalassemia, Bristol Myers Squibb, Acceleron Pharma, REBLOZYL® (luspatercept-aamt), Acceleron

REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent, promotes late-stage red blood cell maturation in animal models.

Key Points: 
  • REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent, promotes late-stage red blood cell maturation in animal models.
  • Bristol Myers Squibb and Acceleron are jointly developing REBLOZYL as part of a global collaboration.
  • In Canada, REBLOZYL is approved for the treatment of adult patients with red blood cell (RBC) transfusion-dependent anemia associated with beta-thalassemia.
  • Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases.

Acceleron to Webcast Third Quarter 2020 Operating and Financial Results on November 5, 2020

Retrieved on: 
Monday, October 26, 2020
Research, Clinical trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Acceleron Pharma, Pulmonary hypertension, PAH, Companies

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, November 5, 2020 at 5:00 p.m. EST to discuss its third quarter 2020 operating and financial results.

Key Points: 
  • Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, November 5, 2020 at 5:00 p.m. EST to discuss its third quarter 2020 operating and financial results.
  • The archived webcast will be available for replay on the Acceleron website approximately two hours after the event.
  • Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases.
  • In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension (PAH), having recently presented positive topline results of the PULSAR Phase 2 trial.

Acceleron Appoints Laura J. Hamill to its Board of Directors

Retrieved on: 
Wednesday, September 16, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Acceleron Pharma, Biotechnology, Gilead Sciences, Life sciences, Articles

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Laura J. Hamill to its Board of Directors.

Key Points: 
  • Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Laura J. Hamill to its Board of Directors.
  • Ms. Hamill brings to the Acceleron board more than three decades of experience in the biopharma industry, serving most recently as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc.
  • Laura is joining our Board at a particularly opportune time as Acceleron is advancing its clinical development plans in an effort to expand its future commercial footprint, said Francois Nader, M.D., Chairman of Acceleron Pharma.
  • Im delighted to join the Board of Acceleron, said Ms. Hamill.